Risk factor
Very high price volatility
Profitability factor
Very low or no dividends
About
Klaria Pharma Holding AB (publ.) operates as a pharmaceutical company in Sweden and internationally. It offers Sumatriptan for the treatment of migraine; and Midazolam for acute epilepsy. The company's clinical phase products include Epinephrine/Adrenaline for the treatment of acute allergic reaction; Naloxone for opioid overdose; and Ketamine for acute pain and depression. It also focuses on the commercialization of cannabis/cannabinoids, including THC and CBD for medical and recreational applications. The company was founded in 2014 and is based in Uppsala, Sweden.
Company Valuation
Considering past and projected metrics, the stock is 'expensive' compared to its peers. In particular, the stock is reasonably priced on P/E.
Target Price
The average target price of KLAR.ST is 1.00 and suggests 5% upside potential. Usually, this means a HOLD recommendation among investment firms. This neutral recommendatio
Buy
Sell